| Bioactivity | MPD2 is a PROTAC (Proteolysis Targeting Chimera) reducer that targets SARS-CoV-2's main protease (MPro). MPD2 reduces MPro protein levels through time-dependent, CRBN (Cereblon) mediated and proteasoma-driven mechanisms. MPD2 has the potential to be an antiviral small molecule compound against a variety of SARS-CoV-2 strains, including drug-resistant strains[1]. |
| Formula | C51H68N6O13 |
| Molar Mass | 973.12 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yugendar R. Alugubelli, et al. Discovery of First-in-Class PROTAC Degraders of SARS-CoV‑2 MainProtease.Journal of Medicinal Chemistry. 2024 Apr 25,67(8):6495-6507. |